PTO/SB/08b (07-09)
Approved for use through 07/31/2012. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1 of 2

Complete If Known	
Application Number	10/552,314-Conf. #1865
Filing Date	September 5, 2006
First Named Inventor	Annie BARDAT
Art Unit	1644
Examiner Name	Y. Kim
Attorney Docket Number	0040-0158PUS1

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	AA*	US-5,945,098	08-31-1999	Sarno et al.	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document Country Code[3]-Number[4]-Kind Code[5] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T[6]
	BA	WO-97/04801-A1	02-13-1997	GENENTECH INC		
	BB	WO-02/092632	11-21-2002	LAB FRANCAIS DU FRACTIONNEMENT		
	BC	WO-2002/013860	02-21-2002	CHUGAI PHARMACEUTICAL CO LTD		√
	BD	JP-61-191622	08-26-1986	Green Cross Corp		√
	BE	EP-0196761-A2	10-08-1986	GREEN CROSS CORP		
	BF	JP-5-025058	02-02-1993	HAGIWARA YOSHIHIDE		√
	BG	EP-0597101	05-18-1994	HAGIWARA HIDEAKI		
	BH	JP-63-088197	04-19-1988	Tosoh Corp		ABS
	BI	JP-9-500894	01-28-1997			ABS
	BJ	WO-98/44948-A2	10-15-1998	CANGENE CORP		
	BK	JP-11-510170	09-07-1999			√
	BL	EP-1314437	05-28-2003	CHUGAI PHARMACEUTICAL CO LTD		

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] CITE NO.: Those application(s) which are marked with an single asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. [2] Applicant's unique citation designation number (optional). [3] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [4] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [5] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [6] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08b (07-09)
Approved for use through 07/31/2012. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 2 of 2

Complete If Known	
Application Number	10/552,314-Conf. #1865
Filing Date	September 5, 2006
First Named Inventor	Annie BARDAT
Art Unit	1644
Examiner Name	Y. Kim
Attorney Docket Number	0040-0158PUS1

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
	CA	BLEEKER, Wim K. et al., "Vasoactive side effects of intravenous immunoglobulin preparations in a rat model and their treatment with recombinant platelet-activating factor acetylhydrolase," *Blood*, March 1, 2000, Vol. 95, No. 5, pp. 1856--1861.	
	CB	PIKAL, Michael J., "Freeze-drying of proteins, part II: Formulation selection," *BioPharm*, October 1990, Vol. 3, No. 9, pp. 26-30.	
	CC	ARAKAWA, Tsutomu et al., "Protein-solvent interactions in pharmaceutical formulations," *Pharmaceutical Research*, 1991, Vol. 8, No. 3, pp. 285-291.	
	CD	OSTERBERG, Thomas et al., "Development of a freeze-dried albumin-free formulation of recombinant factor VIII SQ," *Pharmaceutical Research*, 1997, Vol. 14, No. 7, pp. 892-898.	
	CE	GUO, Wei et al., "Raman evidence that the lyoprotectant poly(ethylene glycol) does not restore nativity to the heme active site of horseradish peroxidase suspended in organic solvents," Biomacromolecules, 2002, Vol. 3, No. 4, pp. 846-849.	
	CF	CHIDWICK, K. et al., "Clinical experience with a new solvent detergent-treated intravenous immunoglobulin free of hypotensive effects," *Vox Sanguinis*, 1999, Vol. 77, No. 4, pp. 204-209.	
	CG	COHN, E. J. et al., "Preparation and properties of serum and plasma proteins. IV. A system for the separation into fractions of the protein and lipoprotein components of biological tissues and fluids," *J. Am. Chem. Soc.*, March 1946, Vol. 68, pp. 459-475.	
	CH	KISTLER, P. et al., "Large scale production of human plasma fractions. Eight years experience with the alcohol fractionation procedure of Nitschmann, Kistler and Lergier," *Vox Sang.*, 1962, Vol. 7, pp. 414-424.	
	CI	STEINBUCH, M. et al., "Isolement de l'immunoglobuline IgG du plasma humain a l'aide de l'acide caprylique," Rev. Fr. Etud. Clin. Biol., Dec. 1969, Vol. 14, No. 10, pp. 1054-1058.	
	CJ	FERNADES, Peter M. et al., "Preparation of a stable intravenous gamma-globulin: Process design and scale-up," *Vox Sang.*, 1980, Vol. 39, No. 2, pp. 101-112.	
	CK	LEVINE, Howard L. et al., "The use of surface tension measurements in the design of antibody-based product formulations," Journal of Parenteral Science & Technology, 1991, Vol. 45, No. 3, pp. 160-165.	
	CL	Pharmacopee Europeenne, 4eme edition, chap. <<Immunoglobuline humaine normale pour administration par voie intraveineuse>>, Methode 2.6.17.	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1]Applicant's unique citation designation number (optional). [2]Applicant is to place a check mark here if English language Translation is attached.